MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
12.89
+0.27
+2.14%
After Hours: 12.50 -0.39 -3.03% 19:33 02/23 EST
OPEN
12.59
PREV CLOSE
12.62
HIGH
12.95
LOW
12.25
VOLUME
508.88K
TURNOVER
0
52 WEEK HIGH
15.65
52 WEEK LOW
4.260
MARKET CAP
704.64M
P/E (TTM)
-5.8850
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Medtronic (MDT) and Astria Therapeutics (ATXS)
Analysts have maintained Buy ratings on Teladoc, Medtronic and Astria Therapeutics. The Healthcare sector has been the subject of a number of analyst upgrades and downgrades in the past week. The analyst consensus for Astria is now a Strong Buy.
TipRanks · 4d ago
Oppenheimer Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
Hartaj Singh from Oppenheimer maintained a Buy rating on Astria Therapeutics with a price target of $25.00. The company’s shares closed yesterday at $13.95. Singh is a 5-star analyst with an average return of 15.1% and a 45.81% success rate.
TipRanks · 4d ago
Weekly Report: what happened at ATXS last week (0212-0216)?
Weekly Report · 6d ago
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Seeking Alpha · 02/14 19:31
Weekly Report: what happened at ATXS last week (0205-0209)?
Weekly Report · 02/12 11:17
Green Plains, Tilly's See Activist Investor Action
Activist Holdings Green Plains Ancora Holdings reported holding 4,176,058 shares of the sustainable bioingredient maker. Tilly's Fund 1 Investments raised its position in the casual-apparel retailer. Apollo Global Management cut its interest in the IT company TD Synnex by a third.
Barron‘s · 02/09 23:45
Astria Therapeutics 10% owner Perceptive Advisors discloses purchase of 2.48M shares
Healthcare On the Move Astria Therapeutics 10% owner Perceptive Advisors discloses purchase of 2.48M shares. ATXS stock up over 6%. Over the last three months, there has been three insider trades in the company. AstriaTherapeutics (NASDAQ:ATXS) The purchase is for a total of 2,481,350 shares.
Seeking Alpha · 02/06 17:46
Buy Rating on Astria Therapeutics Supported by STAR-0215’s Promising Market Potential and Favorable Trial Results
TipRanks · 02/06 13:12
More
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).

Webull offers Astria Therapeutics Inc stock information, including NASDAQ: ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.